Prostate cancer is the most frequently diagnosed cancer in men, with an estimated 241,740 new cases in 2012 in the United States. Although virtually all locally advanced or metastatic sites of tumor are initially reliant on androgen stimulation for growth and respond to treatment with androgen deprivation therapy, inevitably resistance to hormone blockade eventually develops, culminating in the recurrence of highly aggressive castration-resistant prostate cancer (CRPC). Recently published randomized controlled studies focused specifically on this population have led to the emergence of novel therapeutic strategies for patients with CRPC and resulted in a paradigm shift to the multidisciplinary care of this disease. A number of pivotal data sets illustrating the benefits of several novel agents indicate that additional therapeutic options may soon be available that will warrant consideration and integration into prostate cancer care. The treatment landscape and available options for prostate cancer have thus broadened, making choices more challenging for many healthcare professionals and patients, and a once-stagnant systemic treatment algorithm, largely confined to medical or surgical castration, has evolved into delivery of cutting-edge antineoplastic therapy necessitating learning opportunities for urologists and medical oncologists. This CME program uses a roundtable discussion with leading prostate cancer clinical investigators to assist practicing clinicians in formulating up-to-date and appropriate clinical management strategies.

LEARNING OBJECTIVES

• Explore the emerging data and active research evaluating novel agents — including radiopharmaceuticals, androgen biosynthesis inhibitors, antiandrogens and clusterin antisense oligonucleotides — in the setting of advanced prostate cancer, and discuss the biologic basis for their clinical activity.
• Recall existing and emerging research demonstrating the effects of secondary hormonal interventions on quality and quantity of life for patients with chemotherapy-naïve and chemotherapy-pretreated CRPC, and use this information to guide treatment planning for these patients.
• Efficiently identify and educate patients with skeletal metastases about the efficacy and safety of emerging systemic bone-directed treatments.
• Employ case-based learning to effectively apply evidence-based research findings in the determination of best-practice sequencing of available systemic agents for patients with metastatic prostate cancer.
• Counsel appropriately selected patients with minimally symptomatic or asymptomatic advanced prostate cancer about sipuleucel-T as a treatment option, and define an approach to patient monitoring after treatment with this agent.

ACCREDITATION STATEMENT

Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CME credit is no longer available for this issue

CREDIT DESIGNATION STATEMENT

CME credit is no longer available for this issue

HOW TO USE THIS CME ACTIVITY

This CME activity contains an audio component. To receive credit, the participant should listen to the audio MP3s. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

CME credit is no longer available for this issue

CONTENT VALIDATION AND DISCLOSURES

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Dr Slovin had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Beer — Consulting Agreements: Dendreon Corporation, GTx Inc; Paid Research: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cell Therapeutics Inc, Cougar Biotechnology Inc, Dendreon Corporation, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Medivation Inc, Novartis Pharmaceuticals Corporation, OncoGenex Pharmaceuticals Inc; Speakers Bureau: Sanofi. Dr Dreicer — Advisory Committee: EMD Serono Inc, Janssen Pharmaceuticals Inc, Lilly USA LLC, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation. Dr Eisenberger — Advisory Committee: Sanofi; Consulting Agreements: Bristol-Myers Squibb Company, Millennium: The Takeda Oncology Company; Paid Research: Genentech BioOncology, Sanofi. Dr Oh — Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Dendreon Corporation, Janssen Pharmaceuticals Inc, Medivation Inc, Pfizer Inc, Sanofi; Paid Research: Millennium: The Takeda Oncology Company. Dr Petrylak — Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Millennium: The Takeda Oncology Company, Sanofi; Consulting Agreement: Celgene Corporation; Paid Research: Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Eisai Inc, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Lilly USA LLC, Millennium: The Takeda Oncology Company, Sanofi. Dr Sartor — Advisory Committee: Sanofi; Clinical Investigator: AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Millennium: The Takeda Oncology Company, Sanofi; Consulting Agreements: Algeta ASA, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Medivation Inc, Millennium: The Takeda Oncology Company, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Sanofi, Teva Oncology. Dr Smith — Advisory Committee and Consulting Agreements: Amgen Inc, Bayer HealthCare Pharmaceuticals, Millennium: The Takeda Oncology Company; Paid Research: Amgen Inc, Millennium: The Takeda Oncology Company.